Study of endothelial function and vascular stiffness in patients affected by dilated cardiomyopathy on treatment with sacubitril/valsartan.
Endothelial function
sacubitril/valsartan
vascular stiffness
Journal
American journal of cardiovascular disease
ISSN: 2160-200X
Titre abrégé: Am J Cardiovasc Dis
Pays: United States
ID NLM: 101569582
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
01
2022
accepted:
02
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
The multiple beneficial effects of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction are vastly known, but still no or few mentions have been made regarding its effects on endothelial dysfunction and arterial stiffness. To understand more deeply if sacubitril/valsartan may have a role on endothelial function and arterial stiffness, 15 patients with dilated cardiomyopathy with reduced left ventricular ejection fraction (LVEF) were evaluated through transthoracic echocardiography, peripheral arterial tonometry (EndoPAT Aortic stiffness parameters didn't differ after 6 months of treatment. Augmentation pressure (P=0.889), augmentation index (P=0.906) and sphygmic wave velocity (P=0.263) increased slightly, but they weren't found to be statistically significant. Systolic, diastolic, and differential central arterial pressure didn't differ at the beginning and at the end of the study. RHI (reactive hyperemia index) increased significantly after 6 months (P=0.001) as well as augmentation index corrected for 75 bpm. Ejection fraction (32.21% ± 5.7 to 38.43% ± 8.4; P=0.010) and diastolic dysfunction degree (P=0.021) improved. There was an improvement in mitral regurgitation that wasn't statistically significant (P=0.116). TAPSE didn't change while pulmonary systolic arterial pressure increased, although not significantly (22.83 mmHg ± 4 to 27.33 mmHg ± 6; P=0.068) and within the normal range values. Even though in a study with a limited number of patients, sacubitril/valsartan improved endothelial function, left ventricular function, MR, and diastolic function significantly in patients with dilated cardiomyopathy and reduced LVEF. It showed no effects on vascular stiffness.
Sections du résumé
BACKGROUND
BACKGROUND
The multiple beneficial effects of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction are vastly known, but still no or few mentions have been made regarding its effects on endothelial dysfunction and arterial stiffness.
PATIENTS AND METHODS
METHODS
To understand more deeply if sacubitril/valsartan may have a role on endothelial function and arterial stiffness, 15 patients with dilated cardiomyopathy with reduced left ventricular ejection fraction (LVEF) were evaluated through transthoracic echocardiography, peripheral arterial tonometry (EndoPAT
RESULTS
RESULTS
Aortic stiffness parameters didn't differ after 6 months of treatment. Augmentation pressure (P=0.889), augmentation index (P=0.906) and sphygmic wave velocity (P=0.263) increased slightly, but they weren't found to be statistically significant. Systolic, diastolic, and differential central arterial pressure didn't differ at the beginning and at the end of the study. RHI (reactive hyperemia index) increased significantly after 6 months (P=0.001) as well as augmentation index corrected for 75 bpm. Ejection fraction (32.21% ± 5.7 to 38.43% ± 8.4; P=0.010) and diastolic dysfunction degree (P=0.021) improved. There was an improvement in mitral regurgitation that wasn't statistically significant (P=0.116). TAPSE didn't change while pulmonary systolic arterial pressure increased, although not significantly (22.83 mmHg ± 4 to 27.33 mmHg ± 6; P=0.068) and within the normal range values.
CONCLUSIONS
CONCLUSIONS
Even though in a study with a limited number of patients, sacubitril/valsartan improved endothelial function, left ventricular function, MR, and diastolic function significantly in patients with dilated cardiomyopathy and reduced LVEF. It showed no effects on vascular stiffness.
Types de publication
Journal Article
Langues
eng
Pagination
125-135Informations de copyright
AJCD Copyright © 2022.
Déclaration de conflit d'intérêts
None.
Références
Circulation. 2019 Mar 26;139(13):1612-1628
pubmed: 30586761
Circulation. 2019 Mar 12;139(11):1354-1365
pubmed: 30586756
Eur J Echocardiogr. 2009 Jan;10(1):1-25
pubmed: 19065003
J Am Heart Assoc. 2017 Oct 17;6(10):
pubmed: 29042424
J Vasc Res. 2005 Mar-Apr;42(2):101-10
pubmed: 15665545
Am J Hypertens. 2015 Dec;28(12):1409-17
pubmed: 25762811
Am Heart J. 2003 Jul;146(1):168-74
pubmed: 12851627
Exp Physiol. 2008 Jan;93(1):141-7
pubmed: 17965142
Hypertension. 2009 Aug;54(2):409-13
pubmed: 19487582
Mayo Clin Proc Innov Qual Outcomes. 2019 Feb 26;3(1):1-13
pubmed: 30899903
Biochem Biophys Res Commun. 1993 May 28;193(1):248-53
pubmed: 8389145
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Int J Cardiol. 2013 Oct 3;168(3):2426-34
pubmed: 23561919
Cells. 2019 Dec 16;8(12):
pubmed: 31888288
Circ Heart Fail. 2016 Sep;9(9):
pubmed: 27618854
J Am Coll Cardiol. 1994 Nov 15;24(6):1468-74
pubmed: 7930277
J Am Coll Cardiol. 2001 Jan;37(1):195-200
pubmed: 11153738
Circulation. 1997 Oct 7;96(7):2272-9
pubmed: 9337200
Hypertension. 2001 Apr;37(4):1101-7
pubmed: 11304510
Hypertension. 2010 Apr;55(4):855-61
pubmed: 20212267
Int J Cardiol. 2015;186:104-5
pubmed: 25828104
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4239-44
pubmed: 10737768
Hypertension. 2009 Dec;54(6):1328-36
pubmed: 19884567
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Hypertension. 2004 Aug;44(2):112-6
pubmed: 15262901